[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338468-105":59,"doc-detail-338468-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tripartite-motif-containing-protein-50-suppresses-triple-negative-breast-cancer-progression-by-regulating-the-epithelialmesenchymal-transition-research-paper","Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition - Research Paper","","Tripartite motif-containing protein 50 (TRIM50) is investigated as a regulator of tumor progression, with prior evidence showing its overexpression in multiple cancers but limited understanding in breast cancer. The study overexpresses TRIM50 in triple-negative breast cancer cell lines to assess proliferation, clone formation, migration, apoptosis, and epithelial–mesenchymal transition (EMT). TRIM50 upregulation markedly reduces malignant behaviors and promotes apoptosis, while Western blotting links TRIM50 accumulation to SNAI1 mRNA/protein depletion and partial suppression of SNAI1-driven EMT. TRIM50 is also reported to be downregulated in human breast cancer and correlated with reduced invasion.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tripartite-motif-containing-protein-50-suppresses-triple-negative-breast-cancer-progression-by-regulating-the-epithelialmesenchymal-transition-research-paper/338468/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tripartite-motif-containing-protein-50-suppresses-triple-negative-breast-cancer-progression-by-regulating-the-epithelialmesenchymal-transition-research-paper/338468.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is TRIM50 and why is it studied in breast cancer?","Question",{"text":113,"@type":114},"TRIM50 is a recently discovered E3 ubiquitin ligase involved in tumor progression. It is overexpressed in many cancers, but its specific role in breast cancer has been insufficiently studied.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does TRIM50 affect triple-negative breast cancer cell behavior?",{"text":118,"@type":114},"TRIM50 overexpression in triple-negative breast cancer cell lines reduces proliferation, clone formation, and migration, and it increases apoptosis.",{"name":120,"@type":111,"acceptedAnswer":121},"How is TRIM50 linked to SNAI1 and EMT?",{"text":122,"@type":114},"Western blotting shows that accumulated TRIM50 leads to depletion of SNAI1 at both mRNA and protein levels. This partially attenuates epithelial–mesenchymal transition induced by SNAI1.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338468,1790559803,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","CANCER BIOLOGY & THERAPY  \n2024, VOL. 25, NO. 1, 2427410 [https://doi.org/10.1080/15384047.2024.2427410](https://doi.org/10.1080/15384047.2024.2427410)  \nRESEARCH PAPER  \nTripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition  \nDanxiang Chena,b, Jing Jianga,b, Wei Zhanga,b, Xinlin Lia,b, Qidong Gea,b, Xia Liuc, and Xujun Li a,b  \naDepartment of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China; bDepartment of Breast Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China; cDepartment of Anesthesiology, Ningbo 1st Hospital, Ningbo, Zhejiang, China  \nABSTRACT  \nBackground and Objectives: Tripartite motif-containing protein 50 (TRIM50) is a recently discovered E3 ubiquitin ligase that participates in tumor progression. TRIM50 is overexpressed in many cancers, although few studies focused on TRIM50‘s role in breast cancer.  \nMethods: We overexpressed TRIM50 in triple-negative breast cancer cell lines using plasmid and found that TRIM50 upregulation markedly reduced breast cancer cell proliferation, clone formation, and migration, as well as promoted breast cancer cell apoptosis. Western blotting revealed that accumulated TRIM50 resulted in both mRNA and protein depletion of SNAI1, and partially attenuated the epithelial– mesenchymal transition (EMT) induced by SNAI1 .  \nResults: In this study, we demonstrate that TRIM50 is downregulated in human breast cancer and that its overexpression closely correlates with diminished invasion capacity in breast cancer, suggesting that TRIM50 may serve as a diagnostic marker and therapeutic target.  \nConclusion: TRIM50 plays a key role in breast cancer proliferation and potentially serves as a prognostic and therapeutic target.  \nARTICLE HISTORY  \nReceived 31 May 2024 Revised 2 November 2024 Accepted 5 November 2024  \nKEYWORDS  \nTRIM50; EMT; triple-negative breast cancer; biomarker  \nCONTACT Xia Liu  x1881501[1810x@163.com](1810x@163.com)  Department of Anesthesiology, Ningbo 1st Hospital, China; Xujun Li  lxj_breast@163 .com  Department of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China; Qidong Ge  [geqidong1986@126.com](geqidong1986@126.com)  Department of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China  \nThis article was originally published with errors, which have now been corrected in the online version. Please see Correction ([http://dx.doi.org/10.1080/15384047.2025](http://dx.doi.org/10.1080/15384047.2025) . 2585668)  \n© 2024 The Author(s) . Published with license by Taylor & Francis Group, LLC.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript ina repository by the author(s) or with their consent.  \n2  D. CHEN ET AL.  \n1. Introduction  \nFor the past decades, global incidences of breast cancer (BC) have reached 2.3 million cases estimated in the year 2020, gradually outstripping lung carcinoma in morbidity with 11.4% being recorded. 1 The domestic incidences of breast cancer in China reportedly climbed in numbers to 429,105 cases per year in 2022, accompanied by 124,002 BC-specific death cases.2 BCs are characterized by inner genetic heterogeneity, which typically fall into the following three categories: Luminal subtype, human epidermal growth factor receptor 2 (HER2)-positive subtype, and triple-negative breast cancer (TNBC) .3 Afflicted with the absence of intervention targetsand confined by chemotherapy alone, TNBCs only making up a 15–20% proportion of all BC cases tend to be profiled as more clinically invasive and earn more substantial scientific interests4 therein, which elucidates the significance o","cbCaijlCIf1O6SMx","https://ap.wps.com/l/cbCaijlCIf1O6SMx","pdf",6174326,14,"English","# Abstract\n# Background and Objectives\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is TRIM50 and why is it studied in breast cancer?\",\"answer\":\"TRIM50 is a recently discovered E3 ubiquitin ligase involved in tumor progression. It is overexpressed in many cancers, but its specific role in breast cancer has been insufficiently studied.\"},{\"question\":\"How does TRIM50 affect triple-negative breast cancer cell behavior?\",\"answer\":\"TRIM50 overexpression in triple-negative breast cancer cell lines reduces proliferation, clone formation, and migration, and it increases apoptosis.\"},{\"question\":\"How is TRIM50 linked to SNAI1 and EMT?\",\"answer\":\"Western blotting shows that accumulated TRIM50 leads to depletion of SNAI1 at both mRNA and protein levels. This partially attenuates epithelial–mesenchymal transition induced by SNAI1.\"}]","Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition - Research Paper | PDF",1790023745,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7939f5cf1a33a540500db993c7f291e2.webp",983,1280,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff33c3f99ce0772277a3315d0408996f.webp",982,1278,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/526db54d5ce1a9fea99f6ad21cdccb8c.webp",981,1277,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45ad8236874bafa9a76c45abcbaf7645.webp",980,1276]